Market Overview

FBR Capital Initiates TherapeuticsMD At Outperform, Shares Jump

Share:
Related
TherapeuticsMD Makes Innovation In Compliance Packaging For Its Prenatal Vitamins
Goldman Believes TherapeuticsMD Is 'Revitalizing Women's Health,' Initiates With Buy

FBR Capital Markets initiated coverage on shares of TherapeuticsMD (NYSE: TXMD) with an “outperform” rating.

The target price for TherapeuticsMD is set to $34.

TherapeuticsMD shares have jumped 54.10% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

TherapeuticsMD's shares jumped 32.93% to $5.49 in pre-market trading.

Latest Ratings for TXMD

DateFirmActionFromTo
Apr 2016Goldman SachsInitiates Coverage onBuy
Jun 2015GuggenheimInitiates Coverage onBuy
Jul 2014FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBR Capital MarketsInitiation Analyst Ratings

 

Related Articles (TXMD)

View Comments and Join the Discussion!